NO20061161L - Nytt preparat omfattende rosiglitazon og et annet anti-diabetisk middel - Google Patents

Nytt preparat omfattende rosiglitazon og et annet anti-diabetisk middel

Info

Publication number
NO20061161L
NO20061161L NO20061161A NO20061161A NO20061161L NO 20061161 L NO20061161 L NO 20061161L NO 20061161 A NO20061161 A NO 20061161A NO 20061161 A NO20061161 A NO 20061161A NO 20061161 L NO20061161 L NO 20061161L
Authority
NO
Norway
Prior art keywords
rosiglitazone
another anti
new preparation
diabetic agent
dosage form
Prior art date
Application number
NO20061161A
Other languages
English (en)
Inventor
Peter John Coles
Donald Colin Mackenzie
Jr Paul Norman Mudd
Original Assignee
Sb Pharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27840010&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20061161(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sb Pharmco Inc filed Critical Sb Pharmco Inc
Publication of NO20061161L publication Critical patent/NO20061161L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det er beskrevet en oral doseringsform omfattende en eroderbar kjerne, hvilken kjerne omfatter rosiglitazon. eller et farmasøytisk akseptabelt salt eller solvat derav og et annet antidiabetisk middel, hvor kjernen har et belegg med en eller flere åpninger, kjennetegnet ved at belegget er eroderbart under på forhånd bestemte pH-betingelser, det er videre beskrevet en fremgangsmåte for fremstilling av en slik doseringsform og anvendelse av doseringsformen innenfor medisin.
NO20061161A 2003-08-11 2006-03-10 Nytt preparat omfattende rosiglitazon og et annet anti-diabetisk middel NO20061161L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0318824.0A GB0318824D0 (en) 2003-08-11 2003-08-11 Novel composition
PCT/EP2004/008970 WO2005013956A1 (en) 2003-08-11 2004-08-09 Novel composition comprising rosiglitazone and another antidiabetic agent

Publications (1)

Publication Number Publication Date
NO20061161L true NO20061161L (no) 2006-03-10

Family

ID=27840010

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061161A NO20061161L (no) 2003-08-11 2006-03-10 Nytt preparat omfattende rosiglitazon og et annet anti-diabetisk middel

Country Status (37)

Country Link
US (1) US20080206336A1 (no)
EP (1) EP1663191B1 (no)
JP (1) JP4714147B2 (no)
KR (1) KR20060071396A (no)
CN (2) CN1835741B (no)
AP (1) AP2006003489A0 (no)
AR (1) AR045230A1 (no)
AT (1) ATE455542T1 (no)
AU (1) AU2004262933B2 (no)
BR (1) BRPI0413419A (no)
CA (1) CA2534480A1 (no)
CY (1) CY1109923T1 (no)
DE (1) DE602004025257D1 (no)
DK (1) DK1663191T3 (no)
EA (2) EA200800966A1 (no)
EC (1) ECSP066338A (no)
ES (1) ES2339554T3 (no)
GB (1) GB0318824D0 (no)
HK (1) HK1092051A1 (no)
HR (1) HRP20100160T1 (no)
IL (1) IL173177A0 (no)
IS (1) IS2745B (no)
MA (1) MA27996A1 (no)
MX (1) MXPA06001629A (no)
MY (1) MY151053A (no)
NO (1) NO20061161L (no)
NZ (1) NZ544632A (no)
OA (1) OA13233A (no)
PE (1) PE20050357A1 (no)
PL (1) PL1663191T3 (no)
PT (1) PT1663191E (no)
SG (1) SG165178A1 (no)
SI (1) SI1663191T1 (no)
TW (1) TW200517146A (no)
UA (1) UA82537C2 (no)
UY (1) UY28461A1 (no)
WO (1) WO2005013956A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
WO2005051325A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol compositions methods of treatment and delivery
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
CA2731008A1 (en) * 2008-07-18 2010-01-21 Valeant Pharmaceuticals International Modified release formulation and methods of use
WO2011161521A1 (en) * 2010-06-21 2011-12-29 Lupin Limited Compositions comprising metformin and rosiglitazone
MY161846A (en) * 2010-07-09 2017-05-15 James Trinca Green Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
CN105663130B (zh) * 2011-04-15 2019-08-09 江苏豪森药业集团有限公司 一种具有第一和第二活性药物的制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US20020006939A1 (en) * 1997-10-13 2002-01-17 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
CA2327685C (en) * 1998-04-03 2008-11-18 Bm Research A/S Controlled release composition
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
ATE315629T1 (de) * 1998-11-10 2006-02-15 Procter & Gamble Bleichmittelzusammensetzungen
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
SK287038B6 (sk) * 1998-11-12 2009-10-07 Smithkline Beecham Plc Farmaceutický prostriedok na postupné uvoľňovanie 5-[4-[2-(N- metyl-N-(2-pyridyl)amino)etoxy]benzyl]tiazolidín-2,4-diónu a metformínu a spôsob jeho výroby
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
JP2003514011A (ja) * 1999-11-16 2003-04-15 スミスクライン ビーチャム パブリック リミテッド カンパニー チアゾリジンジオン−塩酸メトホルミンを含む医薬組成物
EP1278513B1 (en) * 2000-05-01 2007-07-18 Aeropharm Technology, LLC A core formulation
GB0027471D0 (en) * 2000-11-08 2000-12-27 Smithkline Beecham Plc Processes
GB0120835D0 (en) * 2001-08-28 2001-10-17 Smithkline Beecham Plc Process
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
MY139719A (en) * 2002-02-12 2009-10-30 Glaxo Group Ltd Oral dosage form for controlled drug release
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

Also Published As

Publication number Publication date
ATE455542T1 (de) 2010-02-15
EA200800966A1 (ru) 2009-04-28
BRPI0413419A (pt) 2006-10-10
EP1663191B1 (en) 2010-01-20
TW200517146A (en) 2005-06-01
ECSP066338A (es) 2006-07-28
DK1663191T3 (da) 2010-04-26
JP2007501830A (ja) 2007-02-01
AP2006003489A0 (en) 2006-02-28
WO2005013956A1 (en) 2005-02-17
AU2004262933B2 (en) 2009-12-10
NZ544632A (en) 2009-03-31
CY1109923T1 (el) 2014-09-10
EP1663191A1 (en) 2006-06-07
PT1663191E (pt) 2010-03-16
HK1092051A1 (en) 2007-02-02
OA13233A (en) 2006-12-13
PL1663191T3 (pl) 2010-06-30
MY151053A (en) 2014-03-31
KR20060071396A (ko) 2006-06-26
MXPA06001629A (es) 2006-04-28
HRP20100160T1 (hr) 2010-05-31
CA2534480A1 (en) 2005-02-17
CN1835741B (zh) 2011-12-14
UY28461A1 (es) 2005-03-31
CN102397551A (zh) 2012-04-04
IS8337A (is) 2006-03-02
SG165178A1 (en) 2010-10-28
AU2004262933A1 (en) 2005-02-17
UA82537C2 (uk) 2008-04-25
PE20050357A1 (es) 2005-06-01
JP4714147B2 (ja) 2011-06-29
AR045230A1 (es) 2005-10-19
EA011550B1 (ru) 2009-04-28
US20080206336A1 (en) 2008-08-28
MA27996A1 (fr) 2006-07-03
SI1663191T1 (sl) 2010-05-31
DE602004025257D1 (de) 2010-03-11
ES2339554T3 (es) 2010-05-21
CN1835741A (zh) 2006-09-20
GB0318824D0 (en) 2003-09-10
IS2745B (is) 2011-08-15
EA200600400A1 (ru) 2006-08-25
IL173177A0 (en) 2006-06-11

Similar Documents

Publication Publication Date Title
NO20061161L (no) Nytt preparat omfattende rosiglitazon og et annet anti-diabetisk middel
DE60321351D1 (de) Verfahren zur herstellung von oral verzehrbaren darreichungsformen
DE602005007339D1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
HUP0302553A2 (hu) Egy izotiazol-4-karbonsavamid sói és eljárás az előállításukra és ezek alkalmazására a túlzott mértékű sejtburjánzás visszaszorítására alkalmas gyógyszerkészítmények előállítására
NO20055496D0 (no) Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
NO20061737L (no) Aminosubstituerte erylamino B2 adrenergiske receptoragonister
MX9200992A (es) Composicion farmaceutica que tiene como ingrediente activo 3-[2-(dimetilamino)etil]-n-metil-1h-indol-5-metanosulfonamida y procedimiento para su preparacion.
NO20040268L (no) Nye 2H-pyridazin-3-derivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av den aktive ingrediensen
NO20025029L (no) Nye epotilonderivater, fremgangsmÕte for fremstilling derav og deres farmasöytiske anvendelse
DK1674456T3 (da) Nye 1,4-benzothiazepin-1,1-dioxid-derivater med forbedrede egenskaber, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
JP2008513426A5 (no)
NO20023662D0 (no) Nye heterocykliske derivater, fremgangsmåte ved fremstilling og farmasöytiske sammensetninger inneholdende det samme
AP1736A (en) Oral dosage form for controlled drug release.
DK1169029T3 (da) Anvendelse af sibutramin eller et derivat deraf til behandling af sövnforstyrrelser
ES2323570T3 (es) Nuevas composiciones farmaceuticas que contienen epinastina y pseudoefedrina.
NO20044463L (no) Forbedret modifisert-frigjoringspreparat
HUP0300777A2 (hu) Tiazolidindion-származék tartarátsója
NO20034985L (no) Nye 5-tio-SS-D-xylopyranosid-derivater, fremgangsmåte for fremstilling derav, farmasöytiske blandinger inneholdende dem og den terapeutiskeanvendelse derav
NZ542305A (en) Treatment of proliferative diseases with an epothilone derivative and radiation
HUP0103686A2 (en) Use of rolipram, ariflo or diazepino-indole, triazolo-quinazoline derivatives for the preparation of pharmaceutical compositions preventing or treating diseases associated with an excess in il-12 production
JP2005041866A (ja) 疼痛閾値低下抑制剤
HUP0300770A2 (hu) Tiazolidindion-származék tartarátsója
HUP0302842A2 (hu) Az 1-[6-klór-5-(trifluor-metil)-2-piridinil]-piperazin-hidroklorid kristályalakjai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
TH72850A (th) สารผสมชนิดใหม่

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application